Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: A randomized phase II locally advanced multi-modality protocol

Journal of Clinical Oncology

Volumn 23, Issue 25, 2005, Pages 5883-5891

  Belani, Chandra P ^a   Choy, Hak ^a   Bonomi, Phil ^a   Scott, Charles ^a   Travis, Patrick ^a   Haluschak, John ^a   Curran Jr , Walter J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; VINBLASTINE; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; ESOPHAGITIS; ESOPHAGUS DISEASE; FEMALE; GRANULOCYTOPENIA; HUMAN; HYPERGLYCEMIA; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED; MULTICENTER STUDY; SURVIVAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL ANALYSIS;

EID: 24944542868     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.55.405     Document Type: Article

References (31)

1. American Cancer Society: Cancer Facts and Figures 2004. http://www.cancer.org
2. Glassberg AB, Cornett P: Lung: Non-small cell, in Dollinger M, Rosenbaum EH, Cable G, (eds): Everyone's Guide to Cancer Therapy. Kansas City, MO, Somerville House Books Limited, 1994, pp 469-475
3. Choy H, Devore RF 3rd, Hande KR, et al: A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Int J Radiat Oncol Biol Phys 47:931-937, 2000
4. Perez CA, Stanley K, Grundy G, et al: Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung: Report by the Radiation Therapy Oncology Group. Cancer 50:1091-1099, 1982
5. Perez CA, Bauer M, Edelstein S, et al: Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys 12:539-547, 1986
6. Johnson DH, Einhorn LH, Bartolucci A, et al: Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Intern Med 113:33-38, 1990
7. Le Chevalier T, Arriagada R, Tarayre M, et al: Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. J Natl Cancer Inst 84:58-59, 1992
8. Dillman RO, Seagren SL, Propert KJ, et al: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in Stage III non-small-cell lung cancer. N Engl J Med 323:940-945, 1990
9. Sause WT, Scott C, Taylor S, et al: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87:198-205, 1995
10. Sause W, Kolesar P, Taylor S IV, et al: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:358-364, 2000
11. Schaake-Koning C, van den Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524-530, 1992
12. Jeremic B, Shibamoto Y, Acimovic L, et al: Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: A randomized study. J Clin Oncol 14:1065-1070, 1996
13. Jeremic B, Shibamoto Y, Acimovic L, et al: Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 13:452-458, 1995
14. Dillman RO, Herndon J, Seagren SL, et al: Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88:1210-1215, 1996
15. Curran W, Scott C, Langer, R, et al: Phase III comparison of sequential vs concurrent chemoradiotherapy for pts with unresected stage III non-small cell lung cancer (NSCLC): Report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Amer Soc Clin Oncol 22:2499, 2003 (abstr 303)
16. Furuse K, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699, 1999
17. Rowinsky EK, Donehower RC: Paclitaxel (taxol). N Engl J Med 332:1004-1014, 1995
18. Choy H, Akerley W, Safran H, et al: Multi-institutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 16:3316-3322, 1998
19. Belani CP, Aisner J, Day R, et al: Weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (NSCLC). Proc Amer Soc Clin Oncol 16:448a, 1997 (abstr 1608)
20. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
21. Pfister DG, Johnson DH, Azzoli CG, et al: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 22:330-353, 2004
22. Lau D, Leigh B, Gandara D, et al: Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/ paclitaxel consolidation for stage III non-small-cell lung cancer: A California Cancer Consortium phase II trial. J Clin Oncol 19:442-447, 2001
23. Masters GA, Haraf DJ, Hoffman PC, et al: Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies. Clin Oncol 16: 2157-2163, 1998
24. Vokes EE: Induction chemotherapy followed by concomitant chemoradiotherapy for non-small cell lung cancer. Oncologist 6:25-27, 2001
25. Vokes EE, Herndon JE II, Crawford J, et al: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB NSCLC: Cancer and Leukemia Group B Study 9431. J Clin Oncol 20:4191-4198, 2002
26. Vokes EE, Herndon JE, Kelley MJ, et al: Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): Initial analysis of a randomized phase III trial. Proc Amer Soc Clin Oncol 23:616, 2004 (abstr 7005)
27. Cox JD, Azarnia N, Byhardt RW, et al: A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: Possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group Stage III non-small-cell lung carcinoma-Report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 8:1543-1555, 1990
28. Saunders MI, Dische S, Grosch EJ, et al: Experience with CHART. Int J Radiat Oncol Biol Phys 21:871-878, 1991
29. Saunders MI, Dische S, Barrett A, et al: Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: An interim report-CHART Steering Committee. Br J Cancer 73:1455-1462, 1996
30. Belani CP, Wang W, Johnson DH, et al: Induction chemotherapy followed by standard thoracic radiotherapy (Std. TRT) vs. hyperfractionated accelerated radiotherapy (HART) for patients with unresectable stage III A and B non-small cell lung cancer (NSCLC): Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597). Proc Am Soc Clin Oncol 22:622, 2003 (abstr 2500)
31. Gaspar L, Gandara D, Chansky K, et al: Consolidation docetaxel following concurrent chemoradiotherapy in pathologic stage IIIb non-small cell lung cancer (NSCLC) (SWOG 9504): Patterns of failure and updated survival. Proc Am Soc Clin Oncol 20:315a, 2003 (abstr 1255)